To identify the differences in TOP2A phosphorylation levels with specific phosphorylation sites between normal tissues and primary tumor tissues, the CPTAC module in UALCAN web resource was applied for analysis over six different tumors (breast cancer, colon cancer, kidney renal clear cell carcinoma, lung adenocarcinoma, ovarian cancer, and uterine corpus endometrial carcinoma). This evidence concerns the gene TOP2A and breast carcinoma.